Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 100% |
| Boehringer Ingelheim GmbH-Deals & Alliances Report | Mar 2011 | £380 | 99% |
| Boehringer Ingelheim GmbH Market Share Analysis |
Sep 2010 | £630 | 98% |
| Boehringer Ingelheim GmbH Market Share Analysis | Sep 2010 | £630 | 98% |
| Boehringer Ingelheim GmbH – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 97% |
| Boehringer Ingelheim GmbH Strategic Analysis Profile |
Feb 2008 | £500 | 96% |
| Veterinary Vaccines | Feb 2011 | £2,845 | 80% |
| DPP IV Inhibitors | Sep 2011 | £2,655 | 79% |
| Chronic Obstructive Pulmonary Disease (COPD) Therapeutics PipelineAssessment and Market Forecasts to 2018 |
Aug 2011 | £2,215 | 77% |
| Upstream Processing in Biopharmaceuticals Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market |
Mar 2011 | £2,215 | 75% |
| Thromboembolism - Pipeline Review H2 2011 |
Nov 2011 | £315 | 74% |
| Neurodegenerative Drugs | Apr 2010 | £2,500 | 73% |
| Chronic Obstructive Pulmonary Disease | Feb 2010 | £2,180 | 73% |
| Restless Leg Syndrome (RLS) Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Aug 2011 | £1,265 | 73% |
| Pulmonary Fibrosis - Pipeline Review H2 2011 |
Nov 2011 | £315 | 70% |
| Europe Drug Delivery Devices Market Outlook to 2016 | Nov 2010 | £2,215 | 70% |
| Bronchitis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 70% |
| Type 2 Diabetes - Pipeline Review H2 2011 |
Sep 2011 | £315 | 70% |
| Diabetes - Pipeline Review H2 2011 |
Oct 2011 | £315 | 68% |
| Psoriasis - Pipeline Review H2 2011 |
Sep 2011 | £315 | 68% |
| Myocardial Infarction - Pipeline Review Q3 2011 |
Jul 2011 | £315 | 67% |
| Anti-Inflammatory Therapeutics Market to 2017 Respiratory Diseases and Arthritis Continue to Dominate |
Oct 2011 | £2,215 | 67% |
| Drug Delivery Devices Market Outlook in China to 2016 Inhalation Systems, Infusion Systems and Others |
Aug 2010 | £1,580 | 67% |
| Musculoskeletal Pain - Pipeline Review H2 2011 |
Oct 2011 | £315 | 67% |
| Hormone Refractory Prostate Cancer - Pipeline Review H2 2011 |
Nov 2011 | £315 | 67% |
| Drug Delivery Device Market to 2017 Metered Dose Inhalers and Infusion Pumps to Be Key Revenue Generators |
Sep 2011 | £2,215 | 67% |
| Myocardial Infarction - Pipeline Review H1 2012 |
Jan 2012 | £325 | 66% |
| Lymphoma - Pipeline Review H1 2012 |
Jan 2012 | £325 | 66% |
| Drug Delivery Devices Market Outlook in Canada to 2016 Inhalation Systems, Infusion Systems and Others |
Aug 2010 | £1,580 | 66% |
| Solid Tumor - Pipeline Review H1 2012 |
Jan 2012 | £325 | 66% |
